Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02041611 · ClinicalTrials.gov registry record · NA
Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas
A NA study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT02041611 is a NA study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 20 participants.
The verdict
NCT02041611, a NA study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary goal of this study is evaluate T cell immune status and immune reconstitution and the association with specific cytokines in patients with newly diagnosed HGGs undergoing the standard RT/TMZ and adjuvant TMZ.
Interventions
- PROCEDURE Blood collections
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-07-13 |
| Est. Completion | 2015-12-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02041611
The ClinicalTrials.gov registry entry for NCT02041611 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood collections is the first listed.
NCT02041611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02041611 about?
NCT02041611 is a clinical study titled "Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas". The primary goal of this study is evaluate T cell immune status and immune reconstitution and the association with specific cytokines in patients with newly diagnosed HGGs undergoing the standard RT/TMZ and adjuvant TMZ.
What is the current status of trial NCT02041611?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2012-07-13. Estimated completion is 2015-12-17.
What interventions are being tested in trial NCT02041611?
The interventions under investigation include: Blood collections (PROCEDURE).
Who is sponsoring clinical trial NCT02041611?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.